Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AnGes MG Obtains Patent on eNOS-Induced Angiogenesis
March 8, 2010
- Hospital Managers' Understanding of New Pricing System Essential: Korosho
March 8, 2010
- GLP-1 Agonists More Convenient than DPP-4 Inhibitors: Prof Kadowaki
March 8, 2010
- Paltac to Be Listed on TSE, OSE
March 8, 2010
- NEW PRODUCTS
March 8, 2010
- UBC Opens Its Own Office in Tokyo
March 8, 2010
- 9 Products, Including Pfizer's Lyrica, Recommended for Approval
March 8, 2010
- Daiichi Sankyo to Embark on Generics Business in Japan
March 8, 2010
- BMKK to Break from Long-Listed Drugs: Mr Wright
March 8, 2010
- GRU to Focus on PMDA in 2nd Round of Screening
March 8, 2010
- Surgery-Related Societies to Create Common Database
March 8, 2010
- Takeda to Shore Up Lifestyle Diseases Area in Japan with New Products
March 8, 2010
- Kissei Returns Marketing Right for Cinalong to UCB
March 1, 2010
- Toyama Chemical Initiates PII Trial for T-705 in the US
March 1, 2010
- Maruho to Market Actosin from April
March 1, 2010
- Nippon Shinyaku, Actelion to Codevelop Macitentan for PAH
March 1, 2010
- Takashi Kodama to Be Reelected JPA President
March 1, 2010
- Medipal Ties Up with Medical Ikkou
March 1, 2010
- Dr Hakui Elected as President of Osaka Medical Association
March 1, 2010
- DSP Aims at Increasing Overseas Sales to 50% of Total Sales in FY2014
March 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…